IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 235 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (341 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  Abstract
 » Introduction
 » Case Report
 » Discussion
 »  References

 Article Access Statistics
    Viewed3550    
    Printed116    
    Emailed0    
    PDF Downloaded103    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 


 
 Table of Contents    
DRUG WATCH
Year : 2014  |  Volume : 46  |  Issue : 1  |  Page : 125-126
 

Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma


1 Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
2 Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

Date of Submission22-Jul-2013
Date of Decision03-Aug-2013
Date of Acceptance08-Dec-2013
Date of Web Publication16-Jan-2014

Correspondence Address:
Mehmet A. N. Sendur
Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.125195

Rights and Permissions

 » Abstract 

Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.


Keywords: Adverse drug reactions, bevacizumab, colorectal cancer, necrotizing fasciitis


How to cite this article:
Sendur MA, Aksoy S, Özdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol 2014;46:125-6

How to cite this URL:
Sendur MA, Aksoy S, Özdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol [serial online] 2014 [cited 2023 Mar 26];46:125-6. Available from: https://www.ijp-online.com/text.asp?2014/46/1/125/125195



 » Introduction Top


Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor. The addition of bevacizumab to first or second line chemotherapy was associated with longer overall survival (OS) and progression free survival (PFS) in metastatic colorectal patients. The adverse events associated with bevacizumab include hypertension, proteinuria, thromboembolism, impaired wound healing, bleeding, perforation, reversible leukoencephalopathy syndrome, skin rash, and infusion-related hypersensitivity reactions. [1],[2] We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer.


 » Case Report Top


A 49-year-old man was admitted to clinic with rectal bleeding. Low anterior resection with ileostomy was performed for rectal mass 5 cm from anus. According to the tumor, node, metastases classification, the pathological stage of the carcinoma was T3N1M0 (stage IIIA). The patient was treated with adjuvant 45 Gy chemoradiotherapy with 5-fluorouracil 225 mg/m 2 daily and then fluorouracil-leucovorin-oxaliplatin (FOLFOX4) regimen. After two cycles of FOLFOX4 regimen, serum carcinoembryonic antigen levels had increased. In the radiologic evaluation with chest and abdominal computed tomography, new liver metastases in both lobes were detected. The hepatic metastases were unresectable, hence the patient shifted to regimen of 5-fluorouracil-leucovorin-irinotecan (FOLFIRI). After 12 courses of the FOLFIRI regimen every 2 weeks, the chemotherapy was stopped due to the stable liver metastases. Because of the new metastatic lesions in the liver and pelvic recurrence, bevacizumab added to FOLFIRI regimen. After 10 days of the third cycle of the FOLFIRI-bevacizumab regimen, the patient was admitted with fever, weakness, abdominal pain and erythema of the proximal side of right thigh. The laboratory evaluation revealed a white blood cell count of 22.000/μl (normal value 4,400-11,000/μl) with increased C-reactive protein to 160 mg/l (normal value: 0-10 mg/l). The magnetic resonance imaging (MRI) of the pelvis showed widespread significant air-fluid level abscess in the tissues of right gluteus maximus, gluteus minimus and vastus muscles. A clinical diagnosis of necrotizing fasciitis was made. Ultrasonography-guided drainage of the abscess was performed and 10F pigtail catheter was inserted to the abscess location. The microbiological culture of the material was revealed vancomycin-resistant enterococcus (VRE),  Escherichia More Details coli, and Bacteroides fragilis. The patient was treated with linezolid, imipenem, and metronidazole. Patient responded to treatment for initial few days, but on the 7 th day of the antibiotic treatment, acute renal failure and septic shock was developed. The patient died due to the refractory septic shock.


 » Discussion Top


Necrotizing fasciitis is an uncommon severe soft tissue infection involving the subcutaneous fat and fascia. There are an estimated 3.5 cases of necrotizing fasciitis per 100,000 persons, with a case-fatality rate of 24% despite immediate treatment. [3] Approximately of the 60-70% of cases are polymicrobial. Severe and acute onset of the pain at the infectious site is the most common clinical presentation. The risk factors of necrotizing fasciitis are diabetes mellitus, malnutrion, trauma, operative interventions, and nonsteroidal anti-inflammatory drugs (NSAİDs) usage.[4] Rarely, necrotizing fasciitis can develop due to all-trans-retinoic acid, bisphosphonates, and radiotherapy. [5],[6],[7] In addition, necrotizing fasciitis has also been reported in renal transplant recipient who treated with FK506. [8]

Serious adverse events with bevacizumab treatment were hemorrhage, gastrointestinal perforation, and arterial thromboembolic events. Arterial thromboemebolic events were seen between 1 and 2% of patients during bevacizumab treatment. [9] One of the pathophysiologic mechanism of necrotizing fasciitis is subcutaneous arteries thrombosis and tissue ischemia, bevacizumab can be the etiologic factor for this. [10] The Naranjo probability score revealed that it was probable (+5) that bevacizumab might be responsible for necrotizing fasciitis. We believe that in our patient, necrotizing fasciitis is due to bevacizumab treatment because there was no additional risk factor and there is temporal relationship between necrotizing fasciitis and bevacizumab treatment.

In conclusion, we presented fatal necrotizing fasciitis in a patient during bevacizumab treatment for rectal cancer. Although precise mechanism is not clear, necrotizing fasciitis is a fulminant disease and can be observed during bevacizumab treatment.

 
 » References Top

1.Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.  Back to cited text no. 1
[PUBMED]    
2.Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.  Back to cited text no. 2
[PUBMED]    
3.O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-62.  Back to cited text no. 3
[PUBMED]    
4.Sehgal VN, Sehgal N, Sehgal R, Khandpur S, Sharma S. Necrotizing fasciitis. J Dermatolog Treat 2006;17:184-6.  Back to cited text no. 4
[PUBMED]    
5.Naithani R, Kumar R, Mahapatra M. Fournier's gangrene and scrotal ulcerations during all-trans-retinoic acid therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 2008;5:303-4.  Back to cited text no. 5
    
6.Livengood CH 3rd, Soper JT, Clarke-Pearson DL, Addison WA. Necrotizing fasciitis in irradiated tissue from diabetic women. A report of two cases. J Reprod Med 1991;36:455-8.  Back to cited text no. 6
[PUBMED]    
7.Setabutr D, Hales NW, Krempl GA. Necrotizing fasciitis secondary to bisphosphonate-induced osteonecrosis of the jaw. Am J Otolaryngol 2010;3:127-9.  Back to cited text no. 7
    
8.Tang S, Kwok TK, Ho PL, Tang WM, Chan TM, Lai KN. Necrotizing fasciitis in a renal transplant recipient treated with FK 506: The first reported case. Clin Nephrol 2001;56:481-5.  Back to cited text no. 8
[PUBMED]    
9.Hompes D, Ruers T. Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol 2011;37:737-46.  Back to cited text no. 9
[PUBMED]    
10.Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: Current concepts and review of the literature. J Am Coll Surg 2009;208:279-88.  Back to cited text no. 10
[PUBMED]    



This article has been cited by
1 Fournier's gangrene during lenvatinib treatment: A case report
Martina Barone, Giorgio Grani, Valeria Ramundo, Tiziana Garritano, Cosimo Durante, Rosa Falcone
Molecular and Clinical Oncology. 2020;
[Pubmed] | [DOI]
2 ?????????????????????????A?ß?????????????1?(A case of group A beta streptococcal necrotizing fasciitis in a patient with rectal cancer underwent chemotherapy including bevacizumab)
?? ?? (Hiromi Miyoshi), ?? ??? (Shinichiro Ohshimo), ?? ?? (Yoshiko Kida), ?? ?? (Satoshi Yamaga), ?? ?? (Kohei Ota), ?? ? (Ryu Tsumura), ?? ?? (Nobuaki Shime)
Nihon Kyukyu Igakukai Zasshi: Journal of Japanese Association for Acute Medicine. 2018; 29(1): 36
[Pubmed] | [DOI]
3 Bevacizumab
Reactions Weekly. 2014; 1491(1): 12
[Pubmed] | [DOI]
4 Necrotizing fasciitis caused by Haemophilus influenzae type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report
Tomotaka Ugai,Masataro Norizuki,Takahiro Mikawa,Goh Ohji,Makito Yaegashi
BMC Infectious Diseases. 2014; 14(1): 198
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow